AB-501: Crx-1k, A Novel C. difficile Therapeutic

Antimicrobial resistance has become increasingly prevalent, yet few novel antibiotics have been developed. Professor Mohammad Seyedsayamdost has created his HiTES platform as an approach to rapidly investigate and discover new antibiotic candidates from cryptic metabolites. Crx-1k, an antibiotic for Clostridioides difficile, was discovered through this approach. This novel compound offers a specific, dual mechanism of action that mitigates issues of recurrence in C. diff cases. Alimtas worked with Professor Seyedsayamdost to develop a pitch for venture capital firms and therapeutic companies in the San Francisco area. Following this trip, Alimtas consolidated the company feedback to guide Professor Seyedsayamdost’s future research and spin-out development.